Novartis Beats Analyst Estimates on EPS
Novartis (NYSE: NVS) reported earnings on July 19. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Novartis met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue contracted and GAAP earnings per share contracted.
Gross margins shrank, operating margins dropped, net margins grew.
Novartis logged revenue of $14.30 billion. The 11 analysts polled by S&P Capital IQ predicted a top line of $14.20 billion on the same basis. GAAP reported sales were 3.8% lower than the prior-year quarter's $15.12 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.38. The nine earnings estimates compiled by S&P Capital IQ predicted $1.33 per share. GAAP EPS of $1.11 for Q2 were 0.9% lower than the prior-year quarter's $1.12 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 68.3%, 120 basis points worse than the prior-year quarter. Operating margin was 21.9%, 10 basis points worse than the prior-year quarter. Net margin was 18.6%, 70 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $14.36 billion. On the bottom line, the average EPS estimate is $1.38.
Next year's average estimate for revenue is $57.20 billion. The average EPS estimate is $5.22.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Novartis is outperform, with an average price target of $62.04.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Novartis. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
Add Novartis to My Watchlist.